[Inflammatory breast cancer: clinical course, diagnosis and treatment].
To identify influence of different therapeutic and prognostic factors on survival, a review of the data on treatment of 197 patients with inflammatory breast cancer was carried out at the Dispensary (1994-2004). Multimodal treatment included combinations of radiotherapy, mastectomy and chemotherapy (CMF--75; CAF--98 and taxanes--9). Significantly lower survival was reported for patients with lymph node involvement (N1, N2 and N3) and those without mastectomy and radiotherapy. Overall 10-year survival was registered only in those who had received chemotherapy, radiotherapy and mastectomy (20.2% +/- 5.5); overall 5-year survival was 42.0% +/- 4.8.
Borisov
V I
VI
Chkhikvadze
T V
TV
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007249:Inflammation; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome